Matrix Therapy Company
in Regenerative Medicine

Home
Home
Home

Bringing
Matrix Therapy

from research
to patients

We are a clinical-stage regenerative medical device company developing novel matrix therapies to improve the lives of patients suffering from dermatological and neurological diseases with large unmet medical needs.

Home

The RGTA®

Technology

ReGeneraTing Agents (RGTA®) help restore the natural micro-environment around cells, promoting tissue regeneration.

Home
Home
Home

Research & Development

OTR3® is a biotechnology company with a strong lead in Research and Development, which excellence has been recognized by the European Commission (SME H2020 Instrument) and the French National Research Agency (ANR).

Our Lead Product

CACIPLIQ20®  is the first therapeutic product based on the innovative RGTA® technology.

Home

CACIPLIQ20 ®

This CE marked medical device promotes natural skin regeneration. CACIPLIQ20® is intended to improve the healing of chronic cutaneous ulcers.

Home
Home
Home
Home

© 2022 – OTR3 – All rights reserved

ADDRESS

4, rue Française
75001 Paris, France

© 2022 – OTR3 – All rights reserved